KEGG   DRUG: Etanercept
Entry
D00742                      Drug                                   
Name
Etanercept (USAN/INN);
Etanercept (genetical recombination) (JAN);
Etanercept (genetical recombination) [Etanercept biosimilar 1] (JAN);
Etanercept (genetical recombination) [Etanercept biosimilar 2] (JAN);
Enbrel (TN)
Product
Sequence
LPAQVAFTPY APEPGSTCRL REYYDQTAQM CCSKCSPGQH AKVFCTKTSD TVCDSCEDST
YTQLWNWVPE CLSCGSRCSS DQVETQACTR EQNRICTCRP GWYCALSKQE GCRLCAPLRK
CRPGFGVARP GTETSDVVCK PCAPGTFSNT TSSTDICRPH QICNVVAIPG NASMDAVCTS
TSPTRSMAPG AVHLPQPVST RSQHTQPTPE PSTAPSTSFL LPMGPSPPAE GSTGDEPKSC
DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD
GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK
GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK
  Type
Peptide
Class
Anti-inflammatory
 DG01985  Disease modifying anti-rheumatic drug (DMARD)
  DG01936  TNF inhibitor
Remark
Same as: C07897
Therapeutic category: 3999
ATC code: L04AB01
Product: D00742<JP/US>
Efficacy
Antirheumatic, TNF receptor antagonist
  Disease
Rheumatoid arthritis [DS:H00630]
Polyarticular juvenile idiopathic arthritis [DS:H01672]
Psoriatic arthritis [DS:H01507]
Ankylosing spondylitis [DS:H01674]
Plaque psoriasis [DS:H01656]
Comment
recombinant fusion protein
To decrease signs and symptoms of rheumatoid arthritis
Target
TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]
LTA (TNFB, TNFSF1) [HSA:4049] [KO:K05468]
  Pathway
hsa04010  MAPK signaling pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04064  NF-kappa B signaling pathway
hsa04210  Apoptosis
hsa04350  TGF-beta signaling pathway
hsa04380  Osteoclast differentiation
hsa04612  Antigen processing and presentation
hsa04920  Adipocytokine signaling pathway
hsa05323  Rheumatoid arthritis
Interaction
Structure map
map07050  Antirheumatics - DMARDs and biological agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
     L04AB01 Etanercept
      D00742  Etanercept (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunosuppressants
   Tumor Necrosis Factor (TNF) Blockers
    Etanercept
     D00742  Etanercept (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D00742  Etanercept (USAN/INN); Etanercept (genetical recombination) (JAN); Etanercept (genetical recombination) [Etanercept biosimilar 1] (JAN); Etanercept (genetical recombination) [Etanercept biosimilar 2] (JAN)
Drug groups [BR:br08330]
 Anti-inflammatory
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   DG01936  TNF inhibitor
    D00742  Etanercept
Drug classes [BR:br08332]
 Immunological agent
  DG01936  TNF inhibitor
   D00742  Etanercept
 Antirheumatic agent
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   D00742  Etanercept
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Tumor necrosis factors
    TNF (TNFA, TNFSF2)
     D00742  Etanercept (USAN/INN) <JP/US>
    LTA (TNFB, TNFSF1)
     D00742  Etanercept (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D00742
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D00742
Other DBs
CAS: 185243-69-0
PubChem: 7847807
ChEBI: 4875
NIKKAJI: J2.104.917D
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system